Stereotactic Body Radiation Therapy for Abdominal Oligometastases: a Biological and Clinical Review

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2012 Aug 3

PMID 22852764

Citations 19

Authors

Mohammed Yahia Almaghrabi

Stephane Supiot

Francois Paris

Marc-Andre Mahe

Emmanuel Rio

Affiliations

Soon will be listed here.

Abstract

Advances in imaging and biological targeting have led to the development of stereotactic body radiation therapy (SBRT) as an alternative treatment of extracranial oligometastases. New radiobiological concepts, such as ceramide-induced endothelial apoptosis after hypofractionated high-dose SBRT, and the identification of patients with oligometastatic disease by microRNA expression may yet lead to further developments. Key factors in SBRT are delivery of a high dose per fraction, proper patient positioning, target localisation, and management of breathing-related motion. Our review addresses the radiation doses and schedules used to treat liver, abdominal lymph node (LN) and adrenal gland oligometastases and treatment outcomes. Reported local control (LC) rates for liver and abdominal LN oligometastases are high (median 2-year actuarial LC: 61 -100% for liver oligometastases; 4-year actuarial LC: 68% in a study of abdominal LN oligometastases). Early toxicity is low-to-moderate; late adverse effects are rare. SBRT of adrenal gland oligometastases shows promising results in the case of isolated lesions. In conclusion, properly conducted SBRT procedures are a safe and effective treatment option for abdominal oligometastases.

Citing Articles

Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century.

Mheid S, Allen S, Ng S, Hall W, Sanford N, Aguilera T Curr Oncol. 2023; 30(10):9230-9243.

PMID: 37887567 PMC: 10605011. DOI: 10.3390/curroncol30100667.

Quality assessment of automatically planned O-Ring linac SBRT plans for pelvic lymph node metastases, finding the optimal minimum target size by comparison with robotic SBRT.

Diaz Hernandez K, Unterkirhers S, Schneider U J Appl Clin Med Phys. 2023; 24(12):e14143.

PMID: 37738649 PMC: 10691630. DOI: 10.1002/acm2.14143.

Stereotactic body radiotherapy for the treatment of oligometastatic gynecological malignancy in the abdomen and pelvis: A single-institution experience.

Smile T, Reddy C, Qiao-Guan G, Winter W, Stephans K, Woody N J Radiosurg SBRT. 2021; 7(3):189-197.

PMID: 33898082 PMC: 8055243.

Stereotactic ablative body radiotherapy (SABR) for inoperable, chemorefractory retroperitoneal lymph node relapse from non seminomatous germ cell tumour of testis: a case report.

Gulia A, Anand A, Punnakal A, Kumar A, Patro C, Bansal A BJR Case Rep. 2019; 4(3):20160114.

PMID: 31489207 PMC: 6711267. DOI: 10.1259/bjrcr.20160114.

The effects of N-acetylcysteine on radiotherapy-induced small intestinal damage in rats.

Mercantepe F, Topcu A, Rakici S, Tumkaya L, Yilmaz A Exp Biol Med (Maywood). 2019; 244(5):372-379.

PMID: 30786762 PMC: 6488866. DOI: 10.1177/1535370219831225.

References

Potters L, Kavanagh B, Galvin J, Hevezi J, Janjan N, Larson D . American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010; 76(2):326-32. DOI: 10.1016/j.ijrobp.2009.09.042. View

Pan C, Kavanagh B, Dawson L, Li X, Das S, Miften M . Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010; 76(3 Suppl):S94-100. PMC: 4388033. DOI: 10.1016/j.ijrobp.2009.06.092. View

Herfarth K, Debus J, Lohr F, Bahner M, Rhein B, Fritz P . Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001; 19(1):164-70. DOI: 10.1200/JCO.2001.19.1.164. View

Corre I, Niaudet C, Paris F . Plasma membrane signaling induced by ionizing radiation. Mutat Res. 2010; 704(1-3):61-7. DOI: 10.1016/j.mrrev.2010.01.014. View

Kavanagh B, McGarry R, Timmerman R . Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol. 2006; 16(2):77-84. DOI: 10.1016/j.semradonc.2005.12.003. View

Small R, Lubezky N, Ben-Haim M . Current controversies in the surgical management of colorectal cancer metastases to the liver. Isr Med Assoc J. 2007; 9(10):742-7. View

Scorsetti M, Alongi F, Filippi A, Pentimalli S, Navarria P, Clerici E . Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol. 2012; 51(5):618-23. DOI: 10.3109/0284186X.2011.652738. View

Kavanagh B, Schefter T, Cardenes H, Stieber V, Raben D, Timmerman R . Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006; 45(7):848-55. DOI: 10.1080/02841860600904870. View

Blomgren H, Lax I, Naslund I, Svanstrom R . Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995; 34(6):861-70. DOI: 10.3109/02841869509127197. View

10.

Topkan E, Onal H, Yavuz M . Managing liver metastases with conformal radiation therapy. J Support Oncol. 2008; 6(1):9-13, 15. View

11.

Beitler A, Urschel J, Velagapudi S, Takita H . Surgical management of adrenal metastases from lung cancer. J Surg Oncol. 1998; 69(1):54-7. DOI: 10.1002/(sici)1096-9098(199809)69:1<54::aid-jso11>3.0.co;2-n. View

12.

Kim M, Cho C, Yang K, Lee D, Moon S, Shin Y . Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer. World J Gastroenterol. 2009; 15(48):6091-5. PMC: 2797667. DOI: 10.3748/wjg.15.6091. View

13.

Dawson L, McGinn C, Normolle D, Ten Haken R, Walker S, Ensminger W . Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000; 18(11):2210-8. DOI: 10.1200/JCO.2000.18.11.2210. View

14.

Yin F, Das S, Kirkpatrick J, Oldham M, Wang Z, Zhou S . Physics and imaging for targeting of oligometastases. Semin Radiat Oncol. 2006; 16(2):85-101. DOI: 10.1016/j.semradonc.2005.12.004. View

15.

Fuks Z, Persaud R, Alfieri A, McLoughlin M, Ehleiter D, Schwartz J . Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res. 1994; 54(10):2582-90. View

16.

Yaes R, Kalend A . Local stem cell depletion model for radiation myelitis. Int J Radiat Oncol Biol Phys. 1988; 14(6):1247-59. DOI: 10.1016/0360-3016(88)90404-x. View

17.

MacDermed D, Weichselbaum R, Salama J . A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol. 2008; 98(3):202-6. DOI: 10.1002/jso.21102. View

18.

Phillips R, KARNOFSKY D, Hamilton L, NICKSON J . Roentgen therapy of hepatic metastases. Am J Roentgenol Radium Ther Nucl Med. 1954; 71(5):826-34. View

19.

Higashiyama M, Doi O, Kodama K, Yokouchi H, Imaoka S, Koyama H . Surgical treatment of adrenal metastasis following pulmonary resection for lung cancer: comparison of adrenalectomy with palliative therapy. Int Surg. 1994; 79(2):124-9. View

20.

van der Pool A, Mendez Romero A, Wunderink W, Heijmen B, Levendag P, Verhoef C . Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010; 97(3):377-82. DOI: 10.1002/bjs.6895. View